Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition

Anna K Dewan; Sameer Gupta; Daniel Q Bach; Saagar Jadeja; Scott Granter; Ann LaCasce; Robin Joyce; Matthew S Davids; Victor Huang; Nicole R LeBoeuf

doi:10.1016/j.jdcr.2018.03.005

Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition

JAAD Case Rep. 2019 Apr 20;5(5):401-405. doi: 10.1016/j.jdcr.2018.03.005. eCollection 2019 May.

Authors

Affiliations

¹ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
² Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁵ Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

No abstract available

Keywords: CLL, chronic lymphocytic leukemia; FCR, fludarabine, cyclophosphamide, rituximab; PI3K, phosphoinositide 3-kinase; cutaneous toxicity; immunotherapy; mTOR, mechanistic target of rapamycin; phosphoinositide 3-kinase inhibitors; psoriasis; small molecule inhibitors.

Publication types

Case Reports